AGP Executive Report
Last update: 10 hours agoRegulatory Access Shift (Poland): Poland is revising plans so patients can pick up certain biological medicines, including biosimilars, from local pharmacies instead of only hospitals—aimed at cutting long travel burdens for chronic inflammatory disease care. Cancer Care (FDA): The FDA has granted priority review for perioperative Imfinzi (durvalumab) plus Padcev (enfortumab vedotin) in muscle-invasive bladder cancer patients who can’t take cisplatin, based on the VOLGA trial. Rare Disease (EU): Neuraxpharm and Minoryx’s Nezglyal (leriglitazone) becomes the first EU-approved therapy for cerebral adrenoleukodystrophy in a defined pediatric subgroup. Specialty Pharmacy (Industry): The National Association of Specialty Pharmacy honored 2026 poster award winners and scholarship recipients at inSPire2026, spotlighting real-world outcomes and next-gen leaders. Employer Costs (Healthcare Economics): A new discussion highlights why employer healthcare spending keeps rising, pointing to consolidation and delivery-market power as major drivers. Diagnostics & Manufacturing (India): India’s medical device PLI scheme is credited with starting domestic production of high-end imaging and radiotherapy devices like MRI and CT scanners. Corporate Moves (Diagnostics): Dr Lal PathLabs is buying a 70% stake in SN Genelab to expand genomics and advanced testing services.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
